Gilead Sciences, Inc. “will donate 445,000 vials of AmBisome over five years to help the World Health Organization (WHO) treat more than 50,000 patients with visceral leishmaniasis (VL), also known as kala-azar,” a Gilead press release states, adding, “If sold at Gilead’s no-profit access price, today’s donation would cost more than $8 million.” According to the press release, the initiative is “part of the Gilead Access Program, which aims to provide wider access to the company’s medications to affected populations in the developing world” (12/8).